SCHEMBL6516841

SCHEMBL6516841

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4cccc(Cl)c4Cl)cc32)c(C)c1C(=O)N1CCC[C@H]1CN1CCCC1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.87
FGFR1 P11362 9/20 0.87
PDGFRB P09619 9/20 0.87
MET P08581 7/20 0.87
SRC P12931 4/20 0.87
LCK P06239 3/20 0.87
YES1 P07947 3/20 0.87
ALK Q9UM73 3/20 0.87
CDK2 P24941 2/20 0.87
PTK2B Q14289 2/20 0.87
MEN1 O00255 2/20 0.87
KMT2A Q03164 2/20 0.87
TDP1 Q9NUW8 2/20 0.87
KIT P10721 2/20 0.87
EGFR P00533 2/20 0.87
ABL1 P00519 2/20 0.87
RET P07949 2/20 0.87
FLT3 P36888 2/20 0.87
PLK4 O00444 1/20 0.87
RIOK3 O14730 1/20 0.87

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148118 0.95 KDR (0.87) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93655 0.93 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93656 0.93 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL29376386 0.93 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93657 0.93 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93654 0.93 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL140412 0.93 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL15639801 0.92 KDR (0.99) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL15639803 0.92 KDR (0.99) KDRFGFR1PDGFRBMETSRC
SCHEMBL23691031 0.91 KDR (0.94) KDRFGFR1PDGFRBMETSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 KDR 1077/4885FGFR1 5/4885PDGFRB 467/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 KDR 398/4885FGFR1 637/4885PDGFRB 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.